4.2 Inflammatory Bowel Disease, Coeliac Disease, and Chronic Diarrhoea

Key Takeaways

  • Ulcerative colitis typically produces continuous mucosal colitis extending from the rectum. Crohn’s disease can affect any gastrointestinal segment and often causes patchy inflammation with penetrating or stricturing complications.

  • Suspected acute severe ulcerative colitis warrants urgent admission, infection testing and IV corticosteroids. Review response by day 3. More than eight stools, or three to eight with CRP above 45 mg/L, signals high failure risk and prompts a joint rescue or surgical decision.

  • Assess thrombosis and bleeding risk in hospitalised IBD. Give pharmacological prophylaxis when suitable. Blood-streaked stools alone do not automatically preclude it, but significant active bleeding requires a different assessment.

  • Test for coeliac disease with IgA anti-tTG and total IgA while the patient is eating gluten. Use IgG tests when appropriate in IgA deficiency, and refer when suspicion persists or serology is positive.

  • Test adult infectious diarrhoea when the severity, duration, exposures or host risk warrant it. Bloody diarrhoea needs an assessment for invasive infection or STEC.

Last updated: November 2026

Ulcerative Colitis and Crohn’s Disease

Inflammatory bowel disease (IBD) is diagnosed from the pattern of symptoms, endoscopy, histology, laboratory findings and imaging. Stool testing helps exclude infectious mimics. Outside acute severe colitis, the 2025 ECCO diagnostic guideline recommends ileocolonoscopy with biopsies and assessment with intestinal ultrasound, magnetic resonance enterography or both as appropriate. Sampling different segments helps interpret disease distribution. In acute severe colitis, a limited examination is safer.

FeatureUlcerative colitisCrohn’s disease
DistributionUsually continuous colonic inflammation beginning in the rectum. Treatment can produce patchiness. Mild adjacent terminal ileitis can accompany extensive colitis.Can occur anywhere from the mouth to anus. Ileal, ileocolonic and colonic disease are common. Patchy lesions and rectal sparing support the diagnosis.
EndoscopyErythema, friability, loss of vascular pattern and superficial ulceration. Healed islands can form inflammatory pseudopolyps.Aphthous and deep longitudinal ulcers with intervening swelling can yield a cobblestone appearance.
Histology and depthPrimarily mucosal. Chronic crypt distortion and basal plasmacytosis support chronic colitis. Cryptitis and crypt abscesses reflect activity and can also occur in other colitides.Inflammation can be transmural. Non-crypt-injury granulomas support the diagnosis in context. Many patients lack these on mucosal biopsy. Consider other granulomatous causes where appropriate.
ComplicationsSevere colitis, haemorrhage or toxic megacolon. Longstanding colitis can increase colorectal cancer risk. Assess a new colonic stricture for malignancy.Transmural disease can cause deep fissures, strictures, abscesses and fistulae. Perianal fistulae or pneumaturia from an enterovesical fistula are important clues. Colonic Crohn’s also affects colorectal cancer risk.

For example, recurrent perianal abscesses, a terminal-ileal stricture and intervening normal bowel favour Crohn’s disease. In a patient with new bloody diarrhoea and a continuous inflamed rectum and left colon, ulcerative colitis is more likely. Check for infection and assess the complete pattern even when one clue seems characteristic. Serology such as pANCA or ASCA cannot establish the diagnosis on its own.

Treatment Outside the Acute Severe Pathway

For mild to moderate ulcerative colitis, mesalazine can induce and maintain remission. Choose rectal treatment for proctitis and consider oral and rectal preparations depending on disease extent. Corticosteroids can induce remission in a flare. Plan a steroid-sparing maintenance treatment. In mild to moderate Crohn’s limited to the ileum or ascending colon, locally acting budesonide can induce remission. Oral mesalazine has no routine role in Crohn’s induction or maintenance. More active disease or complications may require advanced therapy or surgery. Treat an abscess or other source of infection with appropriate specialist input before advancing immunosuppression.

Extraintestinal Manifestations and Follow-up

  • Joints and skin. Some peripheral arthritis and erythema nodosum parallel bowel activity. Axial inflammatory back pain can continue independently. Painful ulcers with undermined violaceous edges suggest pyoderma gangrenosum. Seek dermatology input and avoid unnecessary trauma or debridement of active lesions because of pathergy.
  • Eyes. Episcleritis can accompany bowel flares and typically causes mild irritation without loss of vision. Pain with photophobia or visual change warrants urgent ophthalmology assessment for uveitis or another sight-threatening cause.
  • Biliary disease and colorectal surveillance. Primary sclerosing cholangitis (PSC) is associated with IBD and an increased risk of cholangiocarcinoma and colorectal cancer. With coexisting colonic IBD and PSC, arrange annual colonoscopic surveillance from recognition of coexistence. Without PSC, schedule colorectal surveillance using disease duration, extent, previous findings and other risk factors.

ECCO 2026 ulcerative colitis treatment · ECCO Crohn’s treatment · ECCO extraintestinal manifestations · BSG 2025 surveillance

Acute Severe Ulcerative Colitis

The modified Truelove and Witts criteria identify adults who require admission and intensive assessment. Look for six or more bloody stools per day and at least one marker of systemic illness:

  • resting pulse above 90 beats/min
  • temperature above 37.8 °C
  • haemoglobin below 105 g/L
  • CRP above 30 mg/L in the modified criteria, or ESR above 30 mm/hour in the historical criteria

Severe infectious colitis and other diagnoses can produce similar findings. Assess volume status and institute gastroenterology and colorectal surgical review early.

  1. Initial assessment. Record stool frequency, blood loss, vital signs and abdominal findings. Check blood count, CRP, renal function, electrolytes and albumin. Obtain stool samples for enteric pathogens and C. difficile. Assess for a concurrent infection and use the HSE hospital antimicrobial guidance if one is identified or strongly suspected.
  2. Start IV corticosteroids when appropriate. BSG gives hydrocortisone 100 mg IV every six hours or methylprednisolone 30 mg IV every 12 hours as examples. Replace volume and electrolyte losses and provide nutritional support. A limited, gently performed flexible sigmoidoscopy with biopsies can confirm severity and investigate CMV where appropriate. Full colonoscopy and routine bowel preparation increase risk during severe acute colitis.
  3. Assess VTE and bleeding risk. Active IBD and hospitalisation increase thrombosis risk. Offer prophylactic LMWH when no contraindication is present. Minor colitis-related bleeding alone does not usually justify withholding prophylaxis. With clinically significant active haemorrhage or another contraindication, obtain senior review and reassess the prophylaxis plan. Consider the appropriate mechanical measures while pharmacological treatment is unsuitable.
  4. Monitor for toxic megacolon and perforation. Obtain baseline abdominal imaging according to clinical circumstances and repeat it when toxicity continues or distension, worsening pain or suspected complications develop. Non-obstructive colonic dilatation, classically around 6 cm or more in the transverse colon, together with systemic toxicity raises concern for toxic megacolon. Escalate promptly to the colorectal team. Avoid antimotility agents and minimise drugs that reduce gut motility in this setting.

BSG 2025 acute severe colitis pathway · ECCO thromboprophylaxis guidance

Reassess Steroid Response and Escalate

The Oxford (Travis) criteria flag risk on day 3 of IV steroids: more than eight daily bowel motions, or three to eight daily with CRP above 45 mg/L. In the original cohort, 85% of those meeting either criterion underwent colectomy. Use the result as a warning to make a decision with the IBD and surgical teams. The original percentage does not predict an individual’s risk under contemporary care. Worsening toxicity, bleeding or abdominal findings requires earlier action.

Apply the criteria. Six stools and a CRP of 62 mg/L on day 3 meet the second criterion, even if the count has fallen from ten. Reassess the patient’s abdominal findings, physiological stability, infection results and trajectory before choosing rescue or surgery. A negative score also requires continued assessment if symptoms or inflammation persist.

  • Medical rescue. In a patient without an immediate indication for surgery who has inadequate steroid response, consider IV infliximab or IV ciclosporin with specialist input. Review prior therapy, organ function, infection and suitability for maintenance treatment. Begin relevant infection screening on admission when rescue may be needed, including tuberculosis and hepatitis B screening before anti-TNF therapy. Ciclosporin requires drug concentration, renal function, electrolyte and blood pressure monitoring. Specialists select infliximab dosing and consider intensification in selected cases. The PREDICT-UC randomised trial did not show a routine benefit of 10 mg/kg over 5 mg/kg for its day-7 response outcome.
  • Surgery. Perforation, uncontrolled major haemorrhage, peritonitis, clinical deterioration with toxic dilatation or failure of appropriate medical therapy warrants timely colorectal surgery. Avoid waiting for fixed durations of rescue in a deteriorating patient. Subtotal colectomy with end ileostomy and management of the residual rectal stump is a common acute operation. Consider restorative options later, after recovery and multidisciplinary discussion.

Children. Assess for faltering growth and refer suspected IBD to paediatric gastroenterology. In hospitalised children with acute severe colitis, ESPGHAN/ECCO uses the Paediatric Ulcerative Colitis Activity Index (PUCAI). A score above 45 on IV steroid day 3 prompts planning for second-line therapy, and a score of at least 65 on day 5 prompts initiation. Involve the paediatric IBD and surgical teams early. ESPGHAN/ECCO 2025 paediatric guidance

Original Oxford criteria study · PREDICT-UC trial · ASCRS 2026 surgical guideline

Coeliac Disease

Coeliac disease is an immune-mediated enteropathy triggered by dietary gluten in genetically susceptible people. Tissue transglutaminase deamidates gluten peptides, increasing immune recognition in people with susceptible HLA types such as DQ2 and DQ8. Suspect it with unexplained iron deficiency, chronic gastrointestinal symptoms, weight loss or related risk factors. HLA typing is useful in selected uncertain cases because absence of the relevant types makes coeliac disease very unlikely. A positive HLA result alone does not establish the diagnosis.

Investigation

  1. Keep gluten in the diet during assessment. Gluten withdrawal before testing can reduce antibodies and heal mucosal changes. If the patient has already stopped gluten, discuss a supervised gluten challenge with gastroenterology when appropriate.
  2. Test IgA anti-tissue transglutaminase (IgA anti-tTG or anti-TG2) and total IgA. IgA deficiency can cause an uninformative negative IgA result. In confirmed IgA deficiency, use an IgG test such as IgG anti-TG2 or IgG anti-deamidated gliadin peptides. Refer for specialist review if suspicion remains high, including after negative serology. Iron deficiency and weight loss justify continued evaluation.
  3. Confirm through the applicable specialist pathway. For adults undergoing biopsy, the European guideline recommends samples from the distal duodenum and bulb, generally at least four from the second part and two from the bulb. Intraepithelial lymphocytosis, crypt hyperplasia and villous atrophy support coeliac disease in the appropriate serological and clinical setting. Marsh 1 change in isolation is nonspecific. Marsh 2 or 3 change can support confirmation with appropriate serology. Villous atrophy also occurs in other conditions.
  4. Know when a no-biopsy pathway may apply. HSE advises specialist referral for positive tests or persistent suspicion and recommends continuing gluten until confirmation. ESsCD 2025 conditionally supports a specialist no-biopsy pathway for carefully selected adults under 45 with IgA anti-TG2 at least ten times the assay upper limit, confirmatory sampling and no features requiring endoscopy. The 2026 BSG also provides a specialist option for selected symptomatic adults. Follow the local pathway. IgA deficiency and persistent malabsorptive findings with negative serology require a different work-up. The CHI paediatric pathway uses high-titre tTG and confirmatory antibodies, with repeat sampling according to the clinical setting. The ESPGHAN 2020 no-biopsy pathway specifically calls for tTG IgA at least ten times the upper limit and positive EMA IgA in a separate sample.

Management and Follow-up

Arrange dietitian-supported lifelong gluten exclusion after confirmation. Avoid wheat, barley and rye. Many patients tolerate certified gluten-free oats. Review symptoms, nutritional status and how the diet is working. Evaluate and replace relevant deficiencies, such as iron, folate, B12 and vitamin D. Assess osteoporosis risk and arrange DXA when the risk assessment indicates it. Persistent symptoms or weight loss despite an apparently adequate diet require assessment for ongoing exposure, another cause and possible refractory disease. Enteropathy-associated T-cell lymphoma is a rare complication, particularly in refractory disease.

Coeliac disease can be associated with reduced splenic function. Howell–Jolly bodies or other evidence of hyposplenism should prompt a risk review. Use current Irish NIAC recommendations for pneumococcal risk and schedules. In hyposplenia or asplenia, check the additional pneumococcal, meningococcal, Hib and influenza recommendations against age and vaccine history. Review vaccines with the treating team.

HSE coeliac diagnosis · ESsCD adult diagnosis and management · BSG 2026 adult coeliac guideline · ESPGHAN diagnosis · CHI paediatric pathway · NIAC immunisation guidelines

Chronic Diarrhoea

With persistent loose stools for more than four weeks, assess onset, nocturnal symptoms, bleeding, weight loss, medication and diet, exposures and previous surgery. Consider an underlying inflammatory, infectious, malabsorptive or functional cause. Unintentional weight loss, anaemia, blood in stool or a concerning change in bowel habit requires investigation even when an initial stool test is reassuring.

PatternExamples and next steps
WateryReview medicines, laxatives, dietary sugar alcohols and lactose. Consider bile acid diarrhoea, microscopic colitis and functional disease. On colonoscopy, take right and left colonic biopsies when microscopic colitis is suspected, even if the mucosa appears normal.
InflammatoryBlood, urgency or tenesmus may indicate IBD, infection or ischaemia. Interpret inflammatory markers and stool microbiology with the presentation. Cancer also enters the differential for new bowel symptoms with alarm features.
Fat maldigestion or malabsorptionGreasy stool, weight loss and nutritional deficiency can suggest coeliac disease or pancreatic insufficiency. Consider faecal elastase in a formed or semi-solid sample when pancreatic insufficiency is suspected. Values below 100 µg/g support it. A value of 100–200 µg/g is indeterminate in the AGA guidance, and a watery specimen may give a falsely low result.

Faecal calprotectin reflects intestinal neutrophilic inflammation. In suspected IBS without features suggesting cancer, it can help decide whether further evaluation for IBD is needed. Use the local laboratory thresholds and clinical pathway. Infection and some medications can increase it. A low result does not diagnose IBS or exclude all organic disease, including causes such as bile acid diarrhoea and microscopic colitis. For a positive diagnosis of IBS, check for a fitting symptom pattern and use targeted tests to assess important alternatives. In Rome V, the pattern is recurrent abdominal pain or discomfort on at least three days a month over the past three months, with onset at least six months ago, associated with at least two of relation to defaecation, change in stool frequency and change in stool form. When the initial assessment supports IBS, explain the diagnosis, review dietary triggers and symptoms, and tailor initial treatment. Soluble fibre can help, particularly in constipation-predominant IBS. Change the plan if bleeding, weight loss or other alarm features emerge.

Stool Osmotic Gap

A gap can help characterise unexplained watery diarrhoea when stool electrolytes are measured. Estimate it as 290 − 2 × (stool sodium + stool potassium), using an assumed stool water osmolality of 290 mOsm/kg and sodium and potassium in mmol/L. The result is an approximate osmotic gap in mOsm/kg.

  • A low gap, often below 50 mOsm/kg, favours an electrolyte-driven, secretory pattern. Persistent nocturnal symptoms and symptoms despite fasting support the pattern. Consider bile acid diarrhoea, microscopic colitis, medication effects and other causes in context.
  • A clearly high gap supports an excess of unmeasured osmoles, such as from poorly absorbed carbohydrate or magnesium salts. Improvement when the trigger is removed supports an osmotic pattern. Intermediate or conflicting findings may reflect mixed mechanisms.

For example, stool sodium of 35 and potassium of 30 mmol/L give 290 − 2 × 65 = 160 mOsm/kg. A patient who reports using magnesium laxatives has a plausible explanation for this high gap. Ask about dose and frequency, and use history, symptoms and the subsequent course to test that explanation.

Rome V IBS criteria · NICE adult IBS guideline · BSG chronic diarrhoea guideline · AGA faecal elastase advice · Eherer and Fordtran stool osmotic gap study

Assess acute infectious diarrhoea in adults

Check hydration, observations, urine output and ability to drink. Ask about blood, fever, severity and duration, recent travel, food and water, illness in contacts, antibiotic exposure and immunosuppression. Replace fluid and electrolyte losses orally when safe. Suspected sepsis, severe dehydration, persistent vomiting that prevents hydration or peritoneal signs require urgent assessment. In a systemically well adult with short-lived, non-bloody diarrhoea and no high-risk features, supportive care usually suffices.

The HSE community guideline advises stool testing when illness is systemic, diarrhoea is severe or bloody, lasts more than five days, follows travel, or the person is at high risk. Discuss appropriate tests and treatment with microbiology when indicated. Recent antibiotics or healthcare exposure with new unexplained diarrhoea raise suspicion of C. difficile. Test under local guidance and consider enteric precautions. For bloody diarrhoea, include Shiga toxin-producing E. coli and consider Shigella according to exposure history. Avoid routine empiric antibiotics in the stable patient, especially when STEC is suspected, and avoid antimotility agents in inflammatory diarrhoea. Systemic illness needs urgent review and treatment based on the syndrome. Follow HPSC advice for hygiene, outbreak control and relevant public health notification.

HSE infectious diarrhoea prescribing guidance · HPSC shigellosis guidance · IDSA infectious diarrhoea guideline

Loading diagram...
Acute Colitis and Chronic Diarrhoea Decisions
Test Your Knowledge

A 26-year-old man with a 2-year history of ulcerative colitis presents to the acute medical unit with a 4-day history of severe bloody diarrhoea, reporting 9 episodes per day. On physical examination, he appears toxic and flushed. His temperature is 38.3°C, heart rate is 108 bpm, blood pressure is 102/64 mmHg, and respiratory rate is 20 breaths/min. Abdominal examination reveals mild, generalized lower abdominal tenderness without peritonism or guarding. Initial laboratory investigations show: haemoglobin 94 g/L, white cell count 14.8 x 10^9/L, platelets 480 x 10^9/L, serum albumin 26 g/L, and C-reactive protein (CRP) 78 mg/L. A plain abdominal radiograph demonstrates mucosal thickening in the descending colon without colonic dilatation (transverse colon diameter is 3.8 cm). Stool testing for enteric pathogens and Clostridioides difficile is sent. He has blood mixed with stool but no brisk ongoing haemorrhage or other identified contraindication to VTE prophylaxis. What is the most appropriate immediate medical management?

A

Commence oral loperamide 4 mg initially followed by 2 mg after each loose stool, start oral prednisolone 40 mg daily, and discharge with urgent outpatient clinic follow-up

B

Perform immediate full colonoscopy with aggressive polyethylene glycol bowel preparation to determine the proximal extent of ulceration

C

Withhold low-molecular-weight heparin due to active rectal bleeding, initiate oral mesalazine 4 g daily, and request urgent abdominal CT

D

Admit for IV hydrocortisone 100 mg every six hours, appropriate LMWH prophylaxis and close gastroenterology and colorectal review

Test Your Knowledge

A 34-year-old woman is evaluated in the outpatient clinic for chronic fatigue, recurrent abdominal bloating, and iron deficiency anaemia refractory to oral ferrous sulfate. She reports loose bowel motions 2 to 3 times daily without visible blood. Her haemoglobin is 98 g/L with a mean cell volume (MCV) of 72 fL. While still eating gluten, serological testing demonstrates an IgA anti-tissue transglutaminase (IgA-tTG) antibody level of 1.2 U/mL (reference: < 7.0 U/mL, reported as negative). However, total serum IgA is found to be 0.05 g/L (reference: 0.8 - 4.0 g/L). What is the most appropriate next step in establishing the diagnosis?

A

Use IgG anti-tTG or IgG anti-deamidated gliadin peptide serology and refer for specialist assessment with duodenal biopsies

B

Reassure the patient that coeliac disease has been definitively excluded by the negative IgA-tTG, and diagnose irritable bowel syndrome

C

Advise the patient to immediately begin a strict gluten-free diet for 6 months and re-check her IgA-tTG titer

D

Request a colonoscopy with random colonic biopsies to evaluate for microscopic colitis

Test Your Knowledge

A 42-year-old businessman presents with a 6-month history of copious, non-bloody, watery diarrhoea. He reports 5 to 7 voluminous watery stools daily that persist unchanged even when he fasts. He frequently wakes at 3:00 AM with urgency and watery bowel movements. He has lost 4 kg unintentionally. Routine stool microscopy, cultures, and Clostridioides difficile tests are negative. Stool electrolyte testing reveals: stool sodium 110 mmol/L and stool potassium 30 mmol/L. Use an assumed stool water osmolality of 290 mOsm/kg. What is the calculated stool osmotic gap, and which physiological pattern does it support?

A

Stool osmotic gap is 150 mOsm/kg; osmotic diarrhoea caused by unabsorbed dietary carbohydrates

B

Stool osmotic gap is 10 mOsm/kg; osmotic diarrhoea caused by surreptitious magnesium laxative ingestion

C

Stool osmotic gap of 10 mOsm/kg, supporting a predominantly secretory pattern

D

Stool osmotic gap is 120 mOsm/kg; inflammatory diarrhoea caused by extensive ulcerative colitis

Test Your Knowledge

A previously well adult develops abdominal cramps and new bloody diarrhoea after a shared meal. He is alert, drinking, haemodynamically stable and has no fever or signs of sepsis. Which initial plan best fits the Irish community approach?

A

Start loperamide and omit tests because he is afebrile

B

Give an empiric fluoroquinolone solely because blood is present

C

Switch to a gluten-free diet without laboratory testing

D

Assess hydration and severity, send stool for microbiology including evaluation for STEC, and arrange follow-up rather than using routine empiric antibiotics

Sections you finish are checked off in the contents.